In May of 2018, the Federal Joint Committee (G-BA) approved two additional indications for application of PET/CT for management of malignant lymphomas:
- Hodgkin's lymphoma in advanced stage after two cycles of guideline-based chemotherapy;
- Malignant lymphomas in children and adolescents
These indications were added within amendment of the Directive for methods and examinations that are used in hospital settings and Directive methods of the contract medical care that are used in out-patient settings. That means, that procedures are now reimbursed in both hospital and out-patient settings within management of malignant lymphomas. Although, the decision has already been published at the web-site of G-BA, the amendments are not entered in force yet.
See full details in German here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.